Loading...
Marksans Pharma Limited — Naproxen Export Profile: Buyers & Destinations
Loading...
Indian Pharmaceutical Exporter · #8 for Naproxen · $5.1M export value · DGFT Verified
Marksans Pharma Limited is the #8 Indian exporter of Naproxen with $5.1M in export value and 149 verified shipments. Marksans Pharma Limited holds a 3.8% market share in Naproxen exports across 2 countries. The company exports 22 pharmaceutical products worth $125.0M across 11 therapeutic categories.
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.3M | 151 | 99.9% |
| AFGHANISTAN | $6.3K | 1 | 0.1% |
Marksans Pharma Limited exports Naproxen to 2 countries. The largest destination is UNITED STATES accounting for 99.9% of Marksans Pharma Limited's Naproxen shipments. These destinations reflect Marksans Pharma Limited's established distribution network and regulatory approvals in key markets.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| TIME-CAP LABS, | UNITED STATES | $2.8M | 90 |
| TIME-CAP LABS INC | UNITED STATES | $1.0M | 36 |
| TIME-CAP LABS | UNITED STATES | $173.9K | 9 |
| TIME CAP LABS | UNITED STATES | $153.3K | 4 |
| TIME-CAP LABS, INC | UNITED STATES | $89.8K | 8 |
| TIME CAP LABS INC | UNITED STATES | $66.5K | 3 |
| TIME-CAP LABS, INC. | UNITED STATES | $7.7K | 1 |
| FARMAN ORFI LTD | AFGHANISTAN | $6.3K |
Marksans Pharma Limited supplies Naproxen to 8 buyers globally. The largest buyer is TIME-CAP LABS, (UNITED STATES), followed by TIME-CAP LABS INC (UNITED STATES) and TIME-CAP LABS (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
India exported $77.8M worth of Naproxen through 3,414 shipments from 192 suppliers to 76 countries, serving 366 buyers globally. Marksans Pharma Limited contributes $5.1M to this total, accounting for 3.8% of India's Naproxen exports. Marksans Pharma Limited ships Naproxen to 2 countries through 8 buyers.
Marksans Pharma Limited's average Naproxen shipment value is $34.3K per consignment, based on 149 shipments totaling $5.1M. The largest destination is UNITED STATES (99.9% of Marksans Pharma Limited's Naproxen exports).
Marksans Pharma Limited ranks #8 among 192 Indian Naproxen exporters with a 3.8% market share. The top 3 exporters are GLENMARK PHARMACEUTICALS LIMITED ($14.1M), UNICHEM LABORATORIES LIMITED ($13.8M), GRANULES INDIA LIMITED ($8.5M). Marksans Pharma Limited processed 149 shipments to 2 destination countries.
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| NAPROXEN SODIUM TABLETS USP 220MG Batch | $386.5K | 13 |
| NAPROXEN SODIUM TABLETS USP 220MG BATCH | $346.1K | 11 |
| PHARMACEUTICAL PRODUCTS - NAPROXEN SODIUM TABLETS USP 220MG BATCH NO: 140550 | $132.0K | 3 |
| PHARMACEUTICAL PRODUCTS - NAPROXEN SODIUM TABLETS USP 220MG BATCH NO: 140608 | $131.7K | 3 |
| PHARMACEUTICAL PRODUCTS-NAPROXEN SODIUM | $107.5K | 4 |
| PHARMACEUTICAL PRODUCTS - NAPROXEN SODIUM TABLETS USP 220MG Batch No: 150653 | $100.0K | 2 |
| NAPROXEN SODIUM TABLETS USP 220MG (30168 | $89.7K | 2 |
| NAPROXEN SODIUM TABLETS USP 220MG ( 4477680 TABLETS )NOS | $89.0K | 3 |
What Marksans Pharma Limited must comply with to export Naproxen to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #8 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 7 | AUROBINDO PHARMA LTD | $6.3M | 372 | 3 | $16.9K |
| 4 | AMNEAL PHARMACEUTICALS PRIVATE LIMITED | $6.0M | 119 | 1 | $50.0K |
| 8 | MARKSANS PHARMA LIMITED ★ | $5.1M | 149 | 2 | $34.3K |
| 6 | DR.REDDY'S LABORATORIES LTD | $4.0M | 81 | 5 |
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 429 | 12.6% |
| SAHAR AIR CARGO ACC (INBOM4) | 245 | 7.2% |
| SAHAR AIR | 236 | 6.9% |
| DELHI AIR CARGO ACC (INDEL4) | 211 | 6.2% |
| JNPT/ NHAVA SHEVA SEA | 156 | 4.6% |
| HYDERABAD ICD | 145 | 4.2% |
| VIZAG SEA | 140 | 4.1% |
| BANGALORE AIR | 128 | 3.7% |
Marksans Pharma Limited also exports these analgesics & antipyretics products. Each links to the detailed product page.
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Marksans Pharma. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, a crucial maritime route for trade between Asia and Europe. Major shipping lines have introduced an 'Emergency Risk Surcharge' ranging from $250 to $500 per TEU for cargo transiting the Bab-el-Mandeb Strait, effective February 2025. This surcharge elevates shipping costs, potentially impacting the competitiveness of Indian pharmaceutical exports to European and US East Coast markets. (sgeexport.com)
Conversely, the India–European Union Free Trade Agreement (FTA), concluded in January 2026, offers a silver lining. The FTA eliminates tariffs on Indian pharmaceuticals, APIs, vaccines, and medical devices, providing immediate cost relief and enhancing market access for Indian exporters. This development positions Marksans Pharma favorably to increase its footprint in the European market, leveraging its existing regulatory approvals and manufacturing capabilities. (en.wikipedia.org)
Maintaining stringent quality standards is paramount for pharmaceutical exporters. Marksans Pharma has demonstrated a strong commitment to regulatory compliance. In November 2025, the company's Goa facility underwent a current Good Manufacturing Practice (cGMP) inspection by the US FDA, concluding with zero Form 483 observations. This outcome reflects Marksans' dedication to adhering to international quality standards and regulatory requirements. (capitalmarket.com)
Furthermore, the company's subsidiaries have achieved significant regulatory milestones. Time-Cap Laboratories Inc., Marksans' US subsidiary, received an Establishment Inspection Report (EIR) from the US FDA for its New York-based facility in June 2025, following an inspection that resulted in only one observation with no data integrity issues. Such achievements bolster Marksans' reputation as a reliable and compliant pharmaceutical manufacturer. (business-standard.com)
Marksans Pharma Limited exports 22 products worth $125.0M. Beyond Naproxen, top products include Ibuprofen, Amino, Gabapentin, Acetaminophen, Loratadine. View the complete Marksans Pharma Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Naproxen — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Marksans Pharma Limited's Naproxen exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Marksans Pharma Limited
Full Company Profile →
22 products · $125.0M total trade · 11 categories
| 1 |
| NAPROXEN SODIUM TABLETS USP 220MG (15168 |
| $79.2K |
| 3 |
| PHARMACEUTICAL PRODUCTS - NAPROXEN SODIUM TABLETS USP 220MG Batch No: 140854 | $57.3K | 3 |
Marksans Pharma Limited exports 100 distinct Naproxen formulations including tablets, capsules, syrups, and combination drugs. The top formulation is NAPROXEN SODIUM TABLETS USP 220MG Batch with 13 shipments worth $386.5K.
| $50.0K |
| 9 | AUROBINDO PHARMA LIMITED | $3.8M | 183 | 5 | $20.7K |
Marksans Pharma Limited ranks #8 among 192 Indian Naproxen exporters. Average shipment value of $34.3K compared to the market average of $405.2K. The closest competitors by value are AUROBINDO PHARMA LTD and AMNEAL PHARMACEUTICALS PRIVATE LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 76+ countries, 366+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Marksans Pharma Limited.
Request DemoView Pricing →Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Naproxen. For current shipment-level data, contact TransData Nexus.